HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Therapeutic improvement of a stroma-targeted CRAd by incorporating motives responsive to the melanoma microenvironment.

Abstract
We have previously designed a conditionally replicative oncolytic adenovirus (CRAd) named Ad-F512 that can target both the stromal and the malignant melanoma cell compartments. The replication capacity of this CRAd is driven by a 0.5-Kb SPARC promoter fragment (named F512). To improve CRAd's efficacy, we cloned into F512 motives responsive to hypoxia (hypoxia-responsive element (HRE)) and inflammation (nuclear factor kappa B) to obtain a chimeric promoter named κBF512HRE. Using luciferase as a reporter gene, we observed 10-15-fold increased activity under hypoxia and 10-80-fold induction upon tumor necrosis factor-α addition. We next constructed a CRAd (Ad-κBF512HRE) where E1A activity was under κBF512HRE regulation. Treatment of nude mice harboring established tumors made of a mix of SB2 melanoma cells and WI-38 fibroblasts with Ad-κBF512HRE led to the complete elimination of tumors in 100% of mice (8/8). Moreover, Ad-5/3-κBF512HRE, a viral variant pseudotyped with a chimeric 5/3 fiber, exerted a strong lytic effect on CAR-negative melanoma cells and was highly effective in vivo on established tumors made of melanoma cells and WI-38 fibroblasts, leading to the complete elimination of 4/5 tumors. These results indicate that this improved stroma-targeted oncolytic adenovirus can override the resistance of melanoma tumors and might become of significant importance for melanoma therapeutics.
AuthorsDiego L Viale, Eduardo G Cafferata, David Gould, Cecilia Rotondaro, Yuti Chernajovsky, David T Curiel, Osvaldo L Podhajcer, M Veronica Lopez
JournalThe Journal of investigative dermatology (J Invest Dermatol) Vol. 133 Issue 11 Pg. 2576-2584 (Nov 2013) ISSN: 1523-1747 [Electronic] United States
PMID23604101 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Adenoviridae (genetics)
  • Animals
  • Cell Line, Tumor
  • Fibroblasts (cytology)
  • HEK293 Cells
  • Humans
  • Male
  • Melanoma (pathology, therapy)
  • Mice
  • Mice, Nude
  • Oncolytic Virotherapy (methods)
  • Promoter Regions, Genetic (genetics)
  • Skin Neoplasms (pathology, therapy)
  • Stromal Cells (pathology, virology)
  • Tumor Microenvironment (physiology)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: